{
    "cancer_info": {
        "cancer_name": "Cervical Cancer"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "Pelvic MRI (parametrial assessment)",
            "FDG-PET/CT (nodal metastasis evaluation)",
            "CT chest/abdomen/pelvis",
            "Cone biopsy (cold knife preferred)",
            "Endocervical Curettage (ECC)",
            "Cervical biopsy with margin assessment",
            "LVSI assessment",
            "p16 IHC testing",
            "HPV testing",
            "CBC",
            "Renal/hepatic function tests",
            "HIV testing",
            "Cystoscopy/proctoscopy (if bladder/rectal involvement suspected)",
            "SLN mapping with ultrastaging",
            "Comprehensive molecular profiling (PD-L1, MSI-H/dMMR, TMB-H, HER2, NTRK, RET)"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Stage IA1",
            "risk_group": "Low risk (no LVSI)",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "Fertility-sparing candidates",
                    "plan_name": "Cone biopsy",
                    "plan_details": "En bloc excision with ≥1mm clear margins",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Conservative management"
                },
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "Non-fertility-sparing",
                    "plan_name": "Type A hysterectomy",
                    "plan_details": "Simple hysterectomy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Standard"
                }
            ]
        },
        {
            "staging_criteria": "Stage IA2-IB1 (tumors ≤2cm)",
            "risk_group": "Low risk (no LVSI, Silva A/B)",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "Fertility-sparing candidates",
                    "plan_name": "Radical trachelectomy",
                    "plan_details": "Vaginal/abdominal approach + SLN mapping",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Conservative surgery"
                }
            ]
        },
        {
            "staging_criteria": "Stage IB1 (non-conservative)/IB2",
            "risk_group": "Intermediate risk",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "Non-fertility-sparing",
                    "plan_name": "Radical hysterectomy (Type B/C)",
                    "plan_details": "Open approach + pelvic/para-aortic lymphadenectomy",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Alternative treatment",
                    "patient_subgroup": "Locally advanced",
                    "plan_name": "Chemoradiation",
                    "plan_details": "EBRT + brachytherapy + concurrent platinum",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Standard"
                }
            ]
        },
        {
            "staging_criteria": "Stage IB3-IVA",
            "risk_group": "High risk",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "All patients",
                    "plan_name": "Definitive chemoradiation",
                    "plan_details": "EBRT (45 Gy) + brachytherapy (EQD2 ≥85 Gy) + concurrent cisplatin/carboplatin ± pembrolizumab",
                    "nccn_evidence_category": "Category 1 (FIGO 2014)/Category 2B (FIGO 2018)",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Metastatic/Recurrent",
            "risk_group": "Advanced disease",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "PD-L1+ (CPS≥1)",
                    "plan_name": "Pembrolizumab combination",
                    "plan_details": "Pembrolizumab + platinum/taxane ± bevacizumab",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Second-line treatment",
                    "patient_subgroup": "PD-L1+/MSI-H/TMB-H",
                    "plan_name": "Pembrolizumab/Cemiplimab",
                    "plan_details": "Immune checkpoint inhibitors",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Subsequent therapy",
                    "patient_subgroup": "HER2+ (IHC 3+/2+)",
                    "plan_name": "Trastuzumab deruxtecan",
                    "plan_details": "Fam-trastuzumab deruxtecan",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Targeted therapy"
                }
            ]
        },
        {
            "staging_criteria": "Post-hysterectomy",
            "risk_group": "High-risk features",
            "treatment_plans": [
                {
                    "treatment_line": "Adjuvant therapy",
                    "patient_subgroup": "Positive nodes/margins",
                    "plan_name": "Chemoradiation",
                    "plan_details": "Pelvic EBRT + concurrent platinum chemo + brachytherapy",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Standard"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": [
            "PD-L1 (CPS≥1): Predicts response to pembrolizumab/cemiplimab in 1L metastatic disease",
            "MSI-H/dMMR: Indicates immunotherapy benefit (pembrolizumab in 2L+)",
            "TMB-H (≥10 mut/Mb): Predicts pembrolizumab efficacy in 2L+",
            "HER2 (IHC 3+/2+): Guides trastuzumab deruxtecan use",
            "NTRK Fusion: Targetable with larotrectinib/entrectinib",
            "RET Fusion: Targetable with selpercatinib",
            "HPV Status: Prognostic indicator (worse outcomes in HPV-independent subtypes)",
            "Silva Pattern: Predicts nodal metastasis risk (Pattern A: low risk; Pattern C: high risk)"
        ]
    },
    "guideline_id": "（2025.V2）NCCN临床实践指南：宫颈癌.txt"
}